全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
PLOS ONE  2014 

Glucose Deprivation Induces G2/M Transition-Arrest and Cell Death in N-GlcNAc2-Modified Protein-Producing Renal Carcinoma Cells

DOI: 10.1371/journal.pone.0096168

Full-Text   Cite this paper   Add to My Lib

Abstract:

Some cancer cells can survive under glucose deprivation within the microenvironment of a tumor. Recently, we reported that N-linked (β-N-acetylglucosamine)2 [N-GlcNAc2]-modified proteins induce G2/M arrest and cell death under glucose deprivation. Here, we investigated whether such a response to glucose deprivation contributes to the survival of renal cell carcinomas, which are sensitive to nutritional stress. Specifically, we analyzed seven renal carcinoma cell lines. Four of these cell lines produced N-GlcNAc2-modified proteins and led G2/M-phase arrest under glucose deprivation, leading to cell death. The remaining three cell lines did not produce N-GlcNAc2-modified proteins and undergo G1/S-phase arrest under glucose deprivation, leading to survival. The four dead cell lines displayed significant up-regulation in the UDP-GlcNAc biosynthesis pathway as well as increased phosphorylation of p53, which was not observed in the surviving three cell lines. In addition, the four dead cell lines showed prolonged up-regulated expression of ATF3, which is related to unfolded protein response (UPR), while the surviving three cell lines showed only transient up-regulation of ATF3. In this study, we demonstrated that the renal carcinoma cells which accumulate N-GlcNAc2-modified proteins under glucose deprivation do not survive with abnormaly prolonged UPR pathway. By contrast, renal carcinoma cells that do not accumulate N-GlcNAc2-modified proteins under these conditions survive. Morover, we demonstrated that buformin, a UPR inhibitor, efficiently reduced cell survival under conditions of glucose deprivation for both sensitive and resistant phenotypes. Further studies to clarify these findings will lead to the development of novel chemotherapeutic treatments for renal cancer.

References

[1]  Koppenol WH, Bounds PL, Dang CV (2011) Otto warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 69: 325–337.
[2]  El Mjiyad N, Caro-Maldonado A, Ramirez-Peinado S (2011) Munoz-Pinedo (2011) Sugar-free approarches to cancer cell killing. Oncogene 30: 253–264.
[3]  Wu H, Ding Z, Hu D, Sun F, Dai C, et al. (2012) Central role of lactic acidosis in cancer cell resistance to glucose deprivation-induced cell death. J Pathol 227: 189–99.
[4]  Isono T (2011) O-GlcNAc-specific antibody CTD110.6 cross-reacts with N-GlcNAc2-modified proteins induced under glucose deprivation. PLos One 6: e18959.
[5]  Isono T, Chano T, Okabe H, Suzaki M. Isono T (2013) Study of global transcriptional changes of N-GlcNAc2 proteins-producing T24 bladder carcinoma cells under glucose deprivation. PLoS One 8: e60397.
[6]  Hartmann JT, Bokemeyer C (1999) Chemotherapy for renal cell carcinoma. Anticancer Res 19: 1541–3.
[7]  Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156–9.
[8]  Laoukili J, Stahl M, Medema RH (2007) FoxM1: at the crossroads of aging and cancer. Biochem Biophys acta 1775: 92–102.
[9]  Taylor WR, Stark GR (2001) Regulation of G2/M transition by p53. Oncogene 20: 1803–15.
[10]  Saito S, Furuno A, Sakurai J, Sakamoto A, Park HR, et al. (2009) Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation. Canser Res 69: 4225–34.
[11]  Matsuo J, Tukumo Y, Saito S, Tsukahara S, Sakurai J, et al. (2012) Hyperactivation of 4E-binding protein 1 as a mediator of biguanaide induced cytotoxicity during glucose deprivation. Mol cancer Ther 11: 1082–91.
[12]  Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, et al. (2012) Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 30: 2919–28.
[13]  Srinivasan R, Linehan WN (2007) Antiangiogenic therapy in renal cell carcinoma: from concept to reality. Nat Clin Pract Urol 4: 74–5.
[14]  Hidalgo M, Buckner JC, Erlichman C, Pollack MS, Ng Boni JP, et al. (2006) A phase I and phaemacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 12: 5755–63.
[15]  Gupta A, Ming XF, Carvas JM, Yang Z (2009) The hexosamine biosynthesis inhibitor azaserine prevents endothelial inflammation and dysfunction under hyperglycemic condition through antioxidant effects. Am J Physiol Heart Circ Physiol 296: H815–H822.
[16]  Lee AS (2007) GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res 67: 3496–9.
[17]  So AY, da la Fuente E, Walter P, Shuman M, Bemales S (2009) The unfolded protein response during prostate cancer development. Cancer Metastasis Rev 28: 219–23.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133